MedDataX Logo

Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.

NCT ID: NCT06999499

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The background to this research is that frequent medical screening of the general population for melanoma is not feasible. The real challenge of this project is to develop an automatic process for detecting any potential melanoma. To this end, the project aims to design an algorithm to build a novel diagnostic aid that makes use of the similarity and disparity of pigmented lesions in the same patient. To achieve this, we need to obtain and structure a large database of images grouping all pigmented lesions per patient according to their similarities as perceived by dermatologists.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Naevi

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Scanner of the whole body sing the VECTRA 3D

Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma

Group Type EXPERIMENTAL

Scanner of the whole body using the VECTRA 3D

Intervention Type OTHER

Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Scanner of the whole body using the VECTRA 3D

Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 18 and over
* Patient with more than 15 nevi (moles) of various phototypes (I to III)
* Patient who has received information about the study and has not expressed any opposition
* Patient who is a beneficiary or entitled person under a social security scheme

Exclusion Criteria

* Patients with phototype V
* Patients with chronic inflammatory skin diseases
* Claustrophobic patients
* Patients who are bedridden or handicapped
* Patients who are excluded from another research protocol at the time of collection of the non-objection.
* Patients covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women),
* Any other reason which, in the investigator's opinion, could interfere with the evaluation of the research objectives.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital de la Conception

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jilliana MONNIER Dr

Role: CONTACT

Phone: 0491435817

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jilliana MONNIER Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A01109-40

Identifier Type: OTHER

Identifier Source: secondary_id

RCAPHM20_0438

Identifier Type: -

Identifier Source: org_study_id